Updated October 16, 2026: The Second Circuit revived the federal acetaminophen autism and ADHD litigation in July 2026 and denied rehearing on October 16, according to Reuters. Earlier statements that the litigation had effectively ended are no longer current. The appellate rulings do not establish that acetaminophen causes autism or ADHD.
Tylenol autism lawsuits allege that manufacturers and retailers failed to warn about claimed risks from taking acetaminophen during pregnancy. The families contend that prenatal exposure caused autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in their children. The defendants dispute those claims.
Acetaminophen is the active ingredient in Tylenol and many generic pain relievers and fever reducers. Kenvue, the consumer-health business spun off from Johnson & Johnson, makes Tylenol. The litigation also involves retailers that sold store-brand acetaminophen.
Current status of the Tylenol lawsuits
U.S. District Judge Denise Cote excluded the families’ general-causation experts in December 2023. That expert-evidence ruling led to judgments for the defendants because plaintiffs lacked admissible evidence that prenatal acetaminophen exposure could cause the conditions alleged.
The Second Circuit’s July 13, 2026 opinion vacated the judgments and returned the litigation for further proceedings. It held that three experts had been improperly excluded, while upholding the exclusion of two others. The court also rejected the defendants’ federal preemption argument.
On October 16, the appeals court denied requests for panel and en banc rehearing, Reuters reported. That left the July decision reviving about 500 lawsuits intact. The denial could be followed by a request for Supreme Court review; it did not award compensation or resolve liability.
An MDL is not a certified class action
The Judicial Panel on Multidistrict Litigation centralized the litigation on October 5, 2022. The proceeding is MDL No. 3043, In re Acetaminophen – ASD/ADHD Products Liability Litigation, in the Southern District of New York.
Multidistrict litigation coordinates separate cases for pretrial proceedings. It does not automatically turn those cases into a class action or establish that the defendants did anything wrong. Families still have individual claims, and the evidence and applicable law can differ from case to case.
What the families must prove
The claims focus on whether the products should have carried additional pregnancy warnings. The plaintiffs must establish the elements of their claims under the applicable law, including causation. Evidence that a product is capable of causing a condition is distinct from evidence that it caused a particular person’s condition.
The appellate decision concerns which expert opinions can be considered. It does not decide the scientific dispute, find the defendants liable, or guarantee that any particular claim will succeed.
What the research shows
Some observational studies have reported associations between prenatal acetaminophen exposure and autism or ADHD. An association does not by itself show that the medication caused the outcome. Family characteristics, genetics, and the illness being treated can complicate interpretation.
A 2024 Swedish study found no association with autism, ADHD, or intellectual disability in its sibling comparisons. Our review of the research behind the Tylenol autism claims explains the findings and their limitations.
Federal warnings and Kenvue’s response
In September 2025, the FDA initiated a labeling-change process concerning a possible association with autism and ADHD. The agency also acknowledged that causation had not been established and that contrary studies existed.
Kenvue disputes the alleged link and says it will continue defending the cases. Medical organizations have also cautioned that untreated fever and pain during pregnancy can carry risks.
Settlement amounts and potential compensation
The appellate rulings do not create a settlement fund, establish a payout schedule, or provide a basis for predicting an individual recovery. Earlier forecasts that the cases would settle in 2023 or produce exceptionally large awards were unsupported.
Any recovery would depend on the evidence, applicable law, and the outcome of litigation or negotiations. A diagnosis and a history of acetaminophen use alone do not establish entitlement to compensation. Filing deadlines also require individual review; the revival of the litigation should not be assumed to restart them.
Acetaminophen safety and separate liver risks
Acetaminophen overdose can cause serious liver injury. That established risk is separate from the disputed prenatal autism and ADHD claims. Follow the product label, avoid unintentionally combining medicines containing acetaminophen, and consult a clinician about use during pregnancy. A litigation development is not individualized medical advice.
Editorial correction: This article has been revised to distinguish the MDL from a certified class action, correct outdated litigation statements, and replace unsupported liability and payout assertions.
